ATAI Investor Day Presentation Deck

Change From Baseline in the MCCB Overall Composite T-Score 5- Adjusted mean change from baseline in MCCB overall composite T-score with 95% CI 4- 3- 2 1 0- T Baseline I J Week 6 - * I Treatment Group: Placebo QD Week 12 (EoT) *p<0.05 vs placebo CI, confidence interval; EoT, end of treatment; MCCB, MATRICS Cognitive Consensus Battery; MMRM, mixed model repeated measures; QD, once daily Fleischhacker WW, et al. Efficacy and safety of the novel glycine transporter inhibitor BI 425809 once daily in patients with schizophrenia: a double-blind, randomised, placebo- controlled phase 2 study. Lancet Psychiatry. 2021 Mar;8(3):191-201. doi: 10.1016/S2215-0366 (20)30513-7. PMID: 33610228. BI 425809 2 mg QD BI 425809 5 mg QD BI 425809 10 mg QD BI 425809 25 mg QD 19

View entire presentation